Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Genitourinary Drugs Market 

5.1. COVID-19 Landscape: Genitourinary Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Genitourinary Drugs Market, By Indication

8.1. Genitourinary Drugs Market Revenue and Volume, by Indication, 2023-2032

8.1.1. Prostate Cancer

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Ovarian Cancer

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Bladder Cancer

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. Cervical Cancer

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

8.1.5. Renal Cancer

8.1.5.1. Market Revenue and Volume Forecast (2020-2032)

8.1.6. Erectile Dysfunction

8.1.6.1. Market Revenue and Volume Forecast (2020-2032)

8.1.7. Urinary Tract Infections

8.1.7.1. Market Revenue and Volume Forecast (2020-2032)

8.1.8. Urinary Incontinence & Overactive Bladder

8.1.8.1. Market Revenue and Volume Forecast (2020-2032)

8.1.9. Sexually Transmitted Diseases

8.1.9.1. Market Revenue and Volume Forecast (2020-2032)

8.1.10. Interstitial Cystitis

8.1.10.1. Market Revenue and Volume Forecast (2020-2032)

8.1.11. Haematuria

8.1.11.1. Market Revenue and Volume Forecast (2020-2032)

8.1.12. Benign Prostatic Hyperplasia

8.1.12.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Genitourinary Drugs Market, By Product

9.1. Genitourinary Drugs Market Revenue and Volume, by Product, 2023-2032

9.1.1. Urologicals

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Hormonal Therapy

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Gynecological

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

9.1.4. Anti-infectives

9.1.4.1. Market Revenue and Volume Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Genitourinary Drugs Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.1.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.1.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.1.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.5.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.5.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

Chapter 11. Company Profiles

11.1. GlaxoSmithKline

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. AstraZeneca

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. CytoSorbents Corporation

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Cardinal Health

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Asahi Kasei

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. ConvaTec

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. CHIESI Farmaceutici

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Smith & Nephew

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms